Additional data from APPRAISE ATP trial reinforce modular therapy approach with EMBLEM™ Subcutaneous Implantable Defibrillator and EMPOWER™ Leadless Pacemaker
/PRNewswire/ Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the.
CSRWire - Boston Scientific Reports 2023 Actions Toward a Healthier, More Equitable World csrwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from csrwire.com Daily Mail and Mail on Sunday newspapers.
MARLBOROUGH, Mass., April 8, 2024 /PRNewswire/ Boston Scientific Corporation has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module when it is used to visualize and track the.